Lucid Diagnostics (LUCD) Cash & Equivalents (2020 - 2026)

Lucid Diagnostics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $27.9 million for Q1 2026.

• Quarterly Cash & Equivalents rose 10.45% year-over-year to $27.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.9 million (up 10.45% YoY) and the FY2025 annual result came in at $34.7 million, up 55.22% from the prior year.
• Cash & Equivalents was $27.9 million for Q1 2026 at Lucid Diagnostics, down from $34.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $47.9 million in Q1 2022 and bottomed at $14.5 million in Q3 2024.
• A 5-year average of $29.3 million and a median of $26.9 million in 2022 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 126137.35% in 2022, while the deepest fall reached 58.11% in 2022.
• Lucid Diagnostics' Cash & Equivalents stood at $22.5 million in 2022, then declined by 15.92% to $18.9 million in 2023, then rose by 18.32% to $22.4 million in 2024, then soared by 55.22% to $34.7 million in 2025, then retreated by 19.68% to $27.9 million in 2026.
• Business Quant data shows LUCD's Cash & Equivalents at $27.9 million in Q1 2026, $34.7 million in Q4 2025, and $47.3 million in Q3 2025.